Postacute COVID-19 Syndrome : 129Xe MRI Ventilation Defects and Respiratory Outcomes 1 Year Later
Background In individuals with postacute COVID-19 syndrome (PACS) and normal pulmonary function, xenon 129 (129Xe) MRI ventilation defects, abnormal quality-of-life scores, and exercise limitation were reported 3 months after infection; the longitudinal trajectory remains unclear. Purpose To measure and compare pulmonary function, exercise capacity, quality of life, and 129Xe MRI ventilation defect percent (VDP) in individuals with PACS evaluated 3 and 15 months after COVID-19 infection. Materials and Methods In this prospective study, participants with PACS aged 18-80 years were enrolled between July 2020 and August 2021 from two quaternary care centers. 129Xe MRI VDP, diffusing capacity of lung for carbon monoxide (Dlco), spirometry, oscillometry, 6-minute walk distance (6MWD), and St George Respiratory Questionnaire (SGRQ) scores were evaluated 3 months and 15 months after COVID-19 infection. Differences between time points were evaluated using the paired t test. Multivariable models were generated to explain exercise capacity and quality-of-life improvement. Odds ratios (ORs) were used to evaluate potential treatment influences. Results Overall, 53 participants (mean age, 55 years ± 18 [SD]; 27 women) attended both 3- and 15-month visits and were included in the analysis. The mean values for 129Xe MRI VDP (5.8% and 4.2%; P = .003), forced expiratory volume in the 1st second of expiration percent predicted (84% and 90%; P = .001), Dlco percent predicted (86% and 99%; P = .002), and SGRQ score (35 and 25; P < .001) improved between the 3- and 15-month visit. VDP measured 3 months after COVID-19 infection predicted the change in 6MWD (β = -0.643, P = .006), while treatment with respiratory medication at 3 months predicted an improved quality-of-life score at 15 months (OR, 4.0; 95% CI: 1.2, 13.8; P = .03). Conclusion Pulmonary function, gas exchange, exercise capacity, quality of life, and 129Xe MRI ventilation defect percent (VDP) improved in participants with postacute COVID-19 syndrome at 15 months compared with 3 months after infection. VDP measured at 3 months after infection correlated with improved exercise capacity, while treatment with respiratory medication was associated with an improved quality-of-life score 15 months after infection. ClinicalTrials.gov registration no. NCT05014516 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Vogel-Claussen in this issue.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:307 |
|---|---|
| Enthalten in: |
Radiology - 307(2023), 2 vom: 15. Apr., Seite e222557 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Kooner, Harkiran K [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Completed 12.04.2023 Date Revised 29.05.2023 published: Print-Electronic ClinicalTrials.gov: NCT05014516 CommentIn: Radiology. 2023 Feb 7;:230113. - PMID 36749215 Citation Status MEDLINE |
|---|
| doi: |
10.1148/radiol.222557 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM352591552 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM352591552 | ||
| 003 | DE-627 | ||
| 005 | 20231226054058.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1148/radiol.222557 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1175.xml |
| 035 | |a (DE-627)NLM352591552 | ||
| 035 | |a (NLM)36749209 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Kooner, Harkiran K |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Postacute COVID-19 Syndrome |b 129Xe MRI Ventilation Defects and Respiratory Outcomes 1 Year Later |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.04.2023 | ||
| 500 | |a Date Revised 29.05.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a ClinicalTrials.gov: NCT05014516 | ||
| 500 | |a CommentIn: Radiology. 2023 Feb 7;:230113. - PMID 36749215 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Background In individuals with postacute COVID-19 syndrome (PACS) and normal pulmonary function, xenon 129 (129Xe) MRI ventilation defects, abnormal quality-of-life scores, and exercise limitation were reported 3 months after infection; the longitudinal trajectory remains unclear. Purpose To measure and compare pulmonary function, exercise capacity, quality of life, and 129Xe MRI ventilation defect percent (VDP) in individuals with PACS evaluated 3 and 15 months after COVID-19 infection. Materials and Methods In this prospective study, participants with PACS aged 18-80 years were enrolled between July 2020 and August 2021 from two quaternary care centers. 129Xe MRI VDP, diffusing capacity of lung for carbon monoxide (Dlco), spirometry, oscillometry, 6-minute walk distance (6MWD), and St George Respiratory Questionnaire (SGRQ) scores were evaluated 3 months and 15 months after COVID-19 infection. Differences between time points were evaluated using the paired t test. Multivariable models were generated to explain exercise capacity and quality-of-life improvement. Odds ratios (ORs) were used to evaluate potential treatment influences. Results Overall, 53 participants (mean age, 55 years ± 18 [SD]; 27 women) attended both 3- and 15-month visits and were included in the analysis. The mean values for 129Xe MRI VDP (5.8% and 4.2%; P = .003), forced expiratory volume in the 1st second of expiration percent predicted (84% and 90%; P = .001), Dlco percent predicted (86% and 99%; P = .002), and SGRQ score (35 and 25; P < .001) improved between the 3- and 15-month visit. VDP measured 3 months after COVID-19 infection predicted the change in 6MWD (β = -0.643, P = .006), while treatment with respiratory medication at 3 months predicted an improved quality-of-life score at 15 months (OR, 4.0; 95% CI: 1.2, 13.8; P = .03). Conclusion Pulmonary function, gas exchange, exercise capacity, quality of life, and 129Xe MRI ventilation defect percent (VDP) improved in participants with postacute COVID-19 syndrome at 15 months compared with 3 months after infection. VDP measured at 3 months after infection correlated with improved exercise capacity, while treatment with respiratory medication was associated with an improved quality-of-life score 15 months after infection. ClinicalTrials.gov registration no. NCT05014516 © RSNA, 2023 Supplemental material is available for this article. See also the editorial by Vogel-Claussen in this issue | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 700 | 1 | |a McIntosh, Marrissa J |e verfasserin |4 aut | |
| 700 | 1 | |a Matheson, Alexander M |e verfasserin |4 aut | |
| 700 | 1 | |a Abdelrazek, Mohammed |e verfasserin |4 aut | |
| 700 | 1 | |a Albert, Mitchell S |e verfasserin |4 aut | |
| 700 | 1 | |a Dhaliwal, Inderdeep |e verfasserin |4 aut | |
| 700 | 1 | |a Kirby, Miranda |e verfasserin |4 aut | |
| 700 | 1 | |a Ouriadov, Alexei |e verfasserin |4 aut | |
| 700 | 1 | |a Santyr, Giles E |e verfasserin |4 aut | |
| 700 | 1 | |a Venegas, Carmen |e verfasserin |4 aut | |
| 700 | 1 | |a Radadia, Nisarg |e verfasserin |4 aut | |
| 700 | 1 | |a Svenningsen, Sarah |e verfasserin |4 aut | |
| 700 | 1 | |a Nicholson, J Michael |e verfasserin |4 aut | |
| 700 | 1 | |a Parraga, Grace |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Radiology |d 1945 |g 307(2023), 2 vom: 15. Apr., Seite e222557 |w (DE-627)NLM000054860 |x 1527-1315 |7 nnns |
| 773 | 1 | 8 | |g volume:307 |g year:2023 |g number:2 |g day:15 |g month:04 |g pages:e222557 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1148/radiol.222557 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 307 |j 2023 |e 2 |b 15 |c 04 |h e222557 | ||